The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action
Open accessThe DOI matches its Crossref record; 32 of the 34 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function, while the inhibition of α-cell secretion has received less attention. The aim of this research was to quantify the glucagonostatic contribution to the glucose-lowering effect of GLP-1 infusions in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: Ten male patients with well-regulated type 2 diabetes (A1C 6.9 ± 0.8%, age 56 ± 10 years, BMI 31 ± 3 kg/m2 [means ± SD]) were subjected to five 120-min glucose clamps at fasting plasma glucose (FPG) levels. On day 1, GLP-1 was infused to stimulate endogenous insulin release and suppress endogenous glucagon. On days 2–5, pancreatic endocrine clamps were performed using somatostatin infusions of somatostatin and/or selective replacement of insulin and glucagon; day 2, GLP-1 plus basal insulin and glucagon (no glucagon suppression or insulin stimulation); day 3, basal insulin only (glucagon deficiency); day 4, basal glucagon and stimulated insulin; and day 5, stimulated insulin. The basal plasma glucagon levels were chosen to simulate portal glucagon levels. RESULTS: Peptide infusions produced the desired hormone levels. The amount of glucose required to clamp FPG was 24.5 ± 4.1 (day 1), 0.3 ± 0.2 (day 2), 10.6 ± 1.1 (day 3), 11.5 ± 2.7 (day 4), and 24.5 ± 2.6 g (day 5) (day 2 was lower than days 3 and 4, which were both similar and lower than days 1 and 5). CONCLUSIONS: We concluded that insulin stimulation (day 4) and glucagon inhibition (day 3) contribute equally to the effect of GLP-1 on glucose turnover in patients with type 2 diabetes, and these changes explain the glucose-lowering effect of GLP-1 (day 5 vs. day 1).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Considering the prominent role of adipose tissue in energy homeostasis59,172, it is plausible that GIPR agonism in fat could harness beneficial effects on metabolic homeostasis.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [59]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Self-citationNauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 2×
“We employed the pancreatic clamp technique (11) using somatostatin to block the endogenous secretion from the islets while substituting insulin and/or glucagon levels by infusions designed to mimic either basal levels and/or responses to a GLP-1 infusion rate (1 pmol/kg/min) known to normalize blood glucose in patient…”
BackgroundMethodSelf-citationDrucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919 · cited 1×
“The assay reacts equally with intact GLP-1 and with GLP-1 (9–36) amide, the primary metabolite (16).”
MethodSelf-citationGlucagon and regulation of glucose metabolism
Jiang, G., & Zhang, B. B. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00492.2002 · Cited by 905 · cited 1×
“Since in humans the target of glucagon action is the liver (18,19), which is exposed to portal glucagon levels, we chose the portal levels; these were successfully reached (in peripheral plasma) during the glucagon infusions.”
BackgroundDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869 · cited 1×
“Despite their hyperglycemia, patients with type 2 diabetes tend to have elevated fasting glucagon levels and exaggerated glucagon responses to meal ingestion (5).”
BackgroundSelf-citation共やくエクイン・エストロゲン(Premarin)服用閉経婦人の血清エクイリン,エストロン,エストラジオール値
Whittaker, P. G., Morgan, M. R., Dean, P., Cameron, E., & Lind, T. (1980) · The Lancet · Cited by 724
Ahrén, B., Landin-Olsson, M., Jansson, P.-A., Svensson, M., Holmes, D., & Schweizer, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031907 · Cited by 710
Abnormal Alpha-Cell Function in Diabetes: Response to Carbohydrate and Protein Ingestion
Müller, W. A., Faloona, G. R., Aguilar-Parada, E., & Unger, R. H. (1970) · New England Journal of Medicine · doi:10.1056/nejm197007162830301 · Cited by 626
Cited by
Items 101–200 of 275
Short-chain fatty acids as a link between diet and cardiometabolic risk: a narrative review
Birkeland, E., Gharagozlian, S., Valeur, J., & Aas, A. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01803-5 · Cited by 52
Is the Gut the “Sweet Spot” for the Treatment of Diabetes?
Rubino, F., & Amiel, S. A. (2014) · Diabetes · doi:10.2337/db14-0402 · Cited by 41
“However, GLP-1 responses to the intravenous glucose load used in the study are not given and the impact of RYGB on the b-cells and insulin in the islets was mirrored by effects on b-cell and glucagon, at odds with the known glucagon-suppressing effects of GLP1 (19).”
BackgroundBolli, G. B., & Owens, D. R. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12253 · Cited by 36
Fukumori, R., Sugino, T., Shingu, H., Moriya, N., Kobayashi, H., Hasegawa, Y., Kojima, M., Kangawa, K., Obitsu, T., Kushibiki, S., et al. (2013) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2013.09.005 · Cited by 37
“Glucagon-like peptide-1 (7–36) amide is secreted by the small intestine and stimulates insulin secretion [8,18,19].”
BackgroundGlucagon‐Like Peptide‐1: Actions and Influence on Pancreatic Hormone Function
Davis, E., & Sandoval, D. A. (2020) · Comprehensive physiology · doi:10.1002/cphy.c190025 · Cited by 59
The Role of the α Cell in the Pathogenesis of Diabetes: A World beyond the Mirror
Martínez, M. S., Manzano, A., Olivar, L. C., Nava, M., Salazar, J. J., D’Marco, L., Ortíz, R., Chacín, M., Guerrero‐Wyss, M., de Bravo, M. C., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179504 · Cited by 42
“Multiple studies have demonstrated that GLP-1 analogues administration has beneficial effects over HbA1C levels and glucagon serum levels [122–125], and their insulinotropic and glucagonostatic effects are considered equal contributors in T2DM glycaemic control [126].”
BackgroundPleiotropic effects of incretins
Gupta, V. (2012) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.94259 · Cited by 36
Otten, J., Ryberg, M., Mellberg, C., Andersson, T., Chorell, E., Lindahl, B., Larsson, C., Holst, J. J., & Olsson, T. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0082 · Cited by 36
Self-citationGuo, X.-H. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1103214 · Cited by 33
δ-Cells: The Neighborhood Watch in the Islet Community
Gao, R., Yang, T., & Zhang, Q. (2021) · Biology · doi:10.3390/biology10020074 · Cited by 47
“This phenomenon was also described in GLP-1R agonist liraglutide [70], which may account for about half of its glucose-lowering activity [71].”
BackgroundInaba, W., Mizukami, H., Kamata, K., Takahashi, K., Tsuboi, K., & Yagihashi, S. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.07.030 · Cited by 36
“Treatment with DPP-4 inhibitors was reported to suppress hyperglucagonemia in patients with type 2 diabetes (Dunning et al., 2005; Hare et al., 2010).”
BackgroundDerosa, G., Bonaventura, A., Bianchi, L., Romano, D., Fogari, E., D’Angelo, A., & Maffioli, P. (2014) · Metabolism · doi:10.1016/j.metabol.2014.04.008 · Cited by 34
“Vildagliptin and other DPP-4 s, in addition to improving β-cell function, also enhance α-cell function: they suppress inappropriate glucagon secretion as shown after oral glucose andmeal ingestion [9–11], and increase insulin secretion leading to a reduction of hepatic glucose production [12–14].”
BackgroundÅhrén, B., Gautier, J., Berria, R., Stager, W., Aronson, R., & Bailey, C. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12290 · Cited by 33
“Studies now suggest that the glucagonostatic effect of GLP-1 may be at least as important as its insulinotropic effect for its glucose-lowering action [13,28].”
BackgroundTargeting the intestinal L-cell for obesity and type 2 diabetes treatment
Albrechtsen, N. J. W., Kuhre, R. E., Deacon, C. F., & Holst, J. J. (2013) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.862152 · Cited by 34
Self-citationXie, C., Huang, W., Watson, L. E., Soenen, S., Young, R. L., Jones, K. L., Horowitz, M., Rayner, C. K., & Wu, T. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab828 · Cited by 33
Gandasi, N. R., Gao, R., Kothegala, L., Pearce, A., Santos, C., Acreman, S., Basco, D., Benrick, A., Chibalina, M. V., Clark, A., et al. (2024) · Diabetologia · doi:10.1007/s00125-023-06060-w · Cited by 31
Fukumori, R., Mita, T., Sugino, T., Obitsu, T., & Taniguchi, K. (2012) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2012.05.003 · Cited by 31
“Glucagon-like peptide-1 has a glucose-lowering effect through the stimulation of insulin secretion in both nonruminants [1,2] and ruminants [3–5] and through the inhibition of glucagon secretion in humans [6], as well as by its own direct action [7–10].”
BackgroundCell Autonomous Dysfunction and Insulin Resistance in Pancreatic α Cells
Honzawa, N., Fujimoto, K., & Kitamura, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153699 · Cited by 33
“Administration of GLP-1 suppresses glucagon secretion in patients with type 2 diabetes, as measured using a glucose clamp test [66].”
Junker, A. E., Gluud, L. L., van Hall, G., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.014 · Cited by 28
“GLP-1 is secreted from the gastrointestinal tract in response to meal ingestion and triggers insulin secretion and inhibits glucagon secretion at glucose levels above basal [10,11].”
BackgroundSelf-citationSebastiani, G., Ceccarelli, E., Castagna, M. G., & Dotta, F. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.02.005 · Cited by 32
Incretin therapy for diabetes mellitus type 2
Holst, J. J. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000516 · Cited by 32
“experiments in humans, it has been calculated that around 50% of the glucose-lowering effect of GLP-1 in type 2 diabetes is because of inhibition of glucagon secretion whereas the remaining 50% is because of stimulation of insulin secretion [17].”
BackgroundSelf-citationAddy, C., Tatosian, D. A., Glasgow, X. S., Gendrano, I. N., Kauh, E. A., Martucci, A., Johnson‐Levonas, A. O., Selverian, D., Matthews, C. Z., Gutierrez, M., et al. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.12.020 · Cited by 27
Fedorova, N. V., Ksenofontov, A. L., Serebryakova, M. V., Stadnichuk, V. I., Gaponova, T. V., Baratova, L. A., Sud’ina, G. F., & Galkina, S. I. (2018) · Mediators of Inflammation · doi:10.1155/2018/1574928 · Cited by 28
Bagger, J. I., Grøndahl, M. F. G., Lund, A., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2021) · Diabetes · doi:10.2337/db20-0998 · Cited by 27
Self-citationAmbhore, J. P., Laddha, P. R., Nandedkar, A., Ajmire, P. V., Chumbhale, D. S., Navghare, A. B., Kuchake, V., Chaudhari, P. J., & Adhao, V. S. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.135249 · Cited by 27
GLP-1-Based Strategies: A Physiological Analysis of Differential Mode of Action
Burcelin, R., Gourdy, P., & Dalle, S. (2014) · Physiology · doi:10.1152/physiol.00009.2013 · Cited by 26
“In such conditions, GLP-1 decreases glucagon secretion as well as the arginine-induced glucagon response during hyperglycemia (80), which is, in addition to the insulinotropic action of GLP-1, considered to equally contribute to the glucose-lowering action of GLP-1 (52).”
BackgroundSignificant elevation of serum dipeptidyl peptidase-4 activity in young-adult type 1 diabetes
Osawa, S., Kawamori, D., Katakami, N., Takahara, M., Sakamoto, F., Katsura, T., Yasuda, T., Kaneto, H., Matsuhisa, M., Matsuoka, T., et al. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.12.022 · Cited by 28
Investigational glucagon-like peptide-1 agonists for the treatment of obesity
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1221925 · Cited by 25
“The insulin-stimulating effects and glucagon-lowering effects of GLP-1 may contribute to the glucose-lowering action of GLP-1 in patients with T2DM to a similar extent [35].”
BackgroundSchweizer, A., Dejager, S., & Foley, J. E. (2012) · Diabetes Therapy · doi:10.1007/s13300-012-0008-5 · Cited by 27
Chen, Y., & Wang, M. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s334325 · Cited by 25
Bulum, T. (2022) · Biomedicines · doi:10.3390/biomedicines10102586 · Cited by 31
“GLP-1 effects on glucose control in patients with T2DM are equally influenced by beta cell insulin secretion and the inhibition of glucagon secretion from alpha cells [18].”
BackgroundLiu, J., Jin, H., Foreman, R. D., Lei, Y., Xu, X., Li, S., Yin, J., & Chen, J. D. Z. (2014) · Obesity Surgery · doi:10.1007/s11695-014-1521-6 · Cited by 22
“GLP-1 is known to mediate changes in appetite and promote satiety and also plays an important role in regulating blood glucose, acting as a glucose-dependent stimulator of pancreatic insulin secretion [33].”
Postpartum reversibility of impaired incretin effect in gestational diabetes mellitus
Kosiński, M., Knop, F. K., Vedtofte, L., Grycewiczv, J., Swierzewska, P., Cypryk, K., & Vilsbøll, T. (2013) · Regulatory Peptides · doi:10.1016/j.regpep.2013.08.002 · Cited by 25
Self-citationIncretin-Based Therapy and Type 2 Diabetes
Hare, K. J., & Knop, F. K. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00015-1 · Cited by 24
Self-citationLotfy, M. A., Singh, J., Rashed, H., Tariq, S., Zilahi, E., & Adeghate, E. A. (2014) · Cell and Tissue Research · doi:10.1007/s00441-014-1959-9 · Cited by 23
Jensen, S. B. K., Juhl, C. R., Janus, C., Lundgren, J. R., Martinussen, C., Wiingaard, C., Knudsen, C., Frikke‐Schmidt, R., Stallknecht, B. M., Holst, J. J., et al. (2023) · Obesity · doi:10.1002/oby.23715 · Cited by 32
“Glucagon-like peptide-1 (GLP-1) lowers blood glucose via glucose-dependent stimulation of insulin secretion and inhibition of glucagon secretion [13].”
BackgroundSelf-citationGlucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
Berman, C., Vidmar, A. P., & Chao, L. C. (2023) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2023.19.1.38 · Cited by 28
Feigh, M., Andreassen, K. V., Hjuler, S. T., Nielsen, R. H., Christiansen, C., Henriksen, K., & Karsdal, M. A. (2013) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e31827c58ab · Cited by 22
“Furthermore, enhanced hepatic glucose metabolism could be involved in glycemic control, as recently demonstrated by short-term amylin infusion in obese and diabetic rats,49 although this could be indirectly mediated through glucagonostatic action and thus reduction in hepatic glucose production.45 In line with this, w…”
MethodExploring the molecular mechanisms underlying α- and β-cell dysfunction in diabetes
Kawamori, D. (2017) · Diabetology International · doi:10.1007/s13340-017-0327-x · Cited by 23
“One study has indicated that the suppression of glucagon secretion and the augmentation of insulin secretion contribute equally to the glycemic control properties of GLP-1 [70].”
BackgroundSmith, K., Davies, K. A. B., Stevenson, E., & West, D. J. (2020) · Frontiers in Nutrition · doi:10.3389/fnut.2020.587843 · Cited by 24
Glucagon‐like peptide‐1: Are its roles as endogenous hormone and therapeutic wizard congruent?
Holst, J. J. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13433 · Cited by 25
Self-citationRISING STARS: Endocrine regulation of metabolic homeostasis via the intestine and gut microbiome
Meyer, R. K., & Duca, F. A. (2023) · Journal of Endocrinology · doi:10.1530/joe-23-0019 · Cited by 28
Recent achievements and future directions of anti-obesity medications
Grandl, G., Novikoff, A., Liu, X., & Müller, T. D. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.101100 · Cited by 32
SUMO1 enhances cAMP‐dependent exocytosis and glucagon secretion from pancreatic α‐cells
Dai, X., Spigelman, A. F., Khan, S., Braun, M., Fox, J. E. M., & MacDonald, P. E. (2014) · The Journal of Physiology · doi:10.1113/jphysiol.2014.274084 · Cited by 20
“GLP-1 analogues and inhibitors of native GLP-1 degradation are now important tools in the clinical management of diabetes (Lovshin & Drucker, 2009; Hare et al. 2010; Henry et al. 2011; Rauch et al. 2012).”
MethodWu, T., Zhang, X., Trahair, L. G., Bound, M. J., Little, T. J., Deacon, C. F., Horowitz, M., Jones, K. L., & Rayner, C. K. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2813 · Cited by 21
Self-citationGrøndahl, M. F. G., Keating, D. J., Vilsbøll, T., & Knop, F. K. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0967-z · Cited by 23
Self-citationYang, M., Pan, M., Huang, D., Liu, J., Guo, Y., Liu, Y., & Zhang, W. (2023) · Cells · doi:10.3390/cells12071098 · Cited by 19
Jensen, A. H., Winther‐Sørensen, M., Burisch, J. M., Bergquist, A. M., Ytting, H., Gluud, L. L., & Albrechtsen, N. J. W. (2023) · Liver International · doi:10.1111/liv.15720 · Cited by 21
Add-on therapies to metformin for type 2 diabetes
Shomali, M. E. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.542150 · Cited by 19
“In addition to mealassociated insulin stimulation, GLP-1 has been demonstrated to inhibit glucagon secretion both basally and in the postprandial state [40-42].”
BackgroundFAM3D inhibits glucagon secretion via MKP1-dependent suppression of ERK1/2 signaling
Cao, T., Yang, D., Zhang, X., Wang, Y., Qiao, Z., Gao, L., Liang, Y., Yu, B., & Zhang, P. (2017) · Cell Biology and Toxicology · doi:10.1007/s10565-017-9387-8 · Cited by 18
“Both medications reinforce the activity of GLP-1 in glucose-dependent insulin secretion and, as a consequence, potentially reduce glucagon secretion (Hare et al. 2010).”
BackgroundLong-acting glucagon-like peptide-1 receptor agonist—status December 2018
Holst, J. J. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.01.09 · Cited by 21
“It has been demonstrated that the inhibition of glucagon secretion may be responsible for at least 50% of the glucose lowering effects of GLP-1 in T2DM patients (8).”
BackgroundSelf-citationProglucagon-derived peptides: human physiology and therapeutic potential
Gasbjerg, L. S., Nielsen, C. K., Suppli, M. P., Grøndahl, M. F. G., Holst, J. J., Knop, F. K., Jeppesen, P. B., & Lund, A. (2025) · Physiological Reviews · doi:10.1152/physrev.00057.2024 · Cited by 22
Self-citationDomínguez-Vías, G., Segarra, A. B., Ramírez‐Sánchez, M., & Prieto, I. (2020) · Nutrients · doi:10.3390/nu12030636 · Cited by 17
“GLP-1 is an incretin hormone with antidiabetic action that is capable of stimulating insulin secretion [18,19], increasing beta cell neogenesis [20], inhibiting beta cell apoptosis [20], inhibiting glucagon secretion [21], delaying gastric emptying, and inducing satiety [20,21].”
Schneider, R., Kraljević, M., Peterli, R., Rohm, T. V., Klasen, J. M., Cavelti‐Weder, C., & Delko, T. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04750-7 · Cited by 18
“1 Mechanisms by which GLP-1 analogues may have beneficial effects after metabolic surgery: GIT [16, 17], brain [14, 18, 19], cardiovascular system [20, 21], kidneys [22], skeletal muscle [23], adipose tissue [24, 25], liver [26, 27], and endocrine pancreas [15, 28, 29].”
BackgroundGlucagon Clearance Is Preserved in Type 2 Diabetes
Grøndahl, M. F. G., Lund, A., Bagger, J. I., Petersen, T. S., Albrechtsen, N. J. W., Holst, J. J., Vilsbøll, T., Christensen, M., & Knop, F. K. (2021) · Diabetes · doi:10.2337/db21-0024 · Cited by 21
Self-citationGlucagon Clearance Is Decreased in Chronic Kidney Disease but Preserved in Liver Cirrhosis
Grøndahl, M. F. G., Lange, A. H., Suppli, M. P., Bagger, J. I., Thing, M., Gluud, L. L., Kofod, D. H., Hornum, M., van Hall, G., Trammell, S. A. J., et al. (2024) · Diabetes · doi:10.2337/db24-0305 · Cited by 18
“At time (cid:1) 120 min, a primed infusion of isotopically stable [6,6-”
BackgroundSelf-citationDPP‐4 inhibition and islet function
Åhrén, B. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00184.x · Cited by 16
Idorn, T., Knop, F. K., Jørgensen, M. B., Holst, J. J., Hornum, M., & Feldt‐Rasmussen, B. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft353 · Cited by 19
“The secretion of GLP-1 and GIP is stimulated by the intraluminal presence of digested nutrients (carbohydrates, fat and protein) in the gut [7–10] and both hormones possess strong glucose-dependent insulinotropic properties almost immediately after meal intake via binding to specific receptors on the pancreatic beta c…”
BackgroundSelf-citationXie, C., Wang, X., Jones, K. L., Horowitz, M., Sun, Z., Little, T. J., Rayner, C. K., & Wu, T. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13906 · Cited by 19
Glucotoxicity induces abnormal glucagon secretion through impaired insulin signaling in InR1G cells
Katsura, T., Kawamori, D., Aida, E., Matsuoka, T., & Shimomura, I. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176271 · Cited by 18
West, J. A., Ghosh, S. S., Parkes, D. G., Tsakmaki, A., Grønlund, R. V., Pedersen, P. J., MAGGS, D. G., Rajagopalan, H., & Bewick, G. A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249239 · Cited by 19
“Moreover, GLP-1 is a potent inhibitor of appetite, food intake [8] and glucagon secretion [9].”
BackgroundNISHII, N., Takashima, S., Iguchi, A., Murahata, Y., Matsuu, A., Hikasa, Y., & KITAGAWA, H. (2014) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2014.04.006 · Cited by 21
Incretin and glucagon receptor polypharmacology in chronic kidney disease
McFarlin, B. E., Duffin, K. L., & Konkar, A. A. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00374.2023 · Cited by 17
Analysis of Patents Issued in China for Antihyperglycemic Therapies for Type 2 Diabetes Mellitus
Zhu, W. J., Huang, W. R. H., Xu, Z., Cao, M., Hu, Q., Chen, P., Guo, M., Wei, J., & Yuan, H. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00586 · Cited by 17
Forst, T. M., Block, C. E. M. D., Prato, S. D., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., & Schnell, O. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16247 · Cited by 15
“24,25 Along with their effects on alpha and beta cells in the pancreas, incretins modulate the neuroendocrine gut-brain axis with an increase in satiety and a reduction in food intake.”
Signs of Glucagon Resistance After a 2-Week Hypercaloric Diet Intervention
Suppli, M. P., Høgedal, A., Bagger, J. I., Chabanova, E., van Hall, G., Forman, J. L., Christensen, M., Albrechtsen, N. J. W., Holst, J. J., & Knop, F. K. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad666 · Cited by 14
Self-citationFilippello, A., Scamporrino, A., Mauro, S. D., Malaguarnera, R., Pino, A. D., Scicali, R., Purrello, F., & Piro, S. (2020) · Biomolecules · doi:10.3390/biom10101404 · Cited by 15
“In type 2 diabetes (T2D), in contrast to the physiologic state, glucagon hypersecretion arises in hyperglycemic conditions, while glucagon hyposecretion occurs in the hypoglycemic state [4,5], leading to increased plasma glucose and/or prolonged hypoglycemia.”
BackgroundInfluentialØstoft, S. H., Bagger, J. I., Hansen, T. F., Hartmann, B., Pedersen, O. B., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0070 · Cited by 18
Self-citationOkajima, F., Nagamine, T., Nakamura, Y., Hattori, N., Sugihara, H., & Emoto, N. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12588 · Cited by 14
Zhang, H., Song, B., Zhu, W., Liu, L., He, X., Wang, Z., An, K., Cao, W., Shi, J., & Wang, S. (2021) · Aging · doi:10.18632/aging.203351 · Cited by 14
Ding, B., Hu, Y., Yuan, L., Yan, R.-N., & Ma, J.-H. (2021) · Medicine · doi:10.1097/md.0000000000026086 · Cited by 13
“Although glucagon-like peptide-1 receptor agonists (GLP1RAs) are reported as a treatment of glucose lowering by the inhibition of glucagon secretion and promotion of insulin secretion in patients with type 2 diabetes,([2]) and one of the underlying causes of late dumping syndrome is thought to be the postoperatively e…”
BackgroundHoteit, B. H., Kotaich, J., Ftouni, H., Hazime, F., Safawi, A., Masri, R., & Marwani, M. (2025) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188251383064 · Cited by 21
“23,24 Moreover, significant weight loss in patients with PCOS or overweight was seen after the use of GLP-1RAs as a mono-therapy or combined with metformin, showing the beneficial metabolic role of these analogs.”
Beyond Weight Loss: Optimizing GLP-1 Receptor Agonist Use in Children
Zaitoon, H., Wauters, A. D., Rodríguez, L. M., & Lynch, J. L. (2025) · Children · doi:10.3390/children12111427 · Cited by 15
“In youth with impaired glucose tolerance or early type 2 diabetes, these dual effects can improve oral glucose tolerance profiles and reduce glycemic variability, thereby mitigating the β -cell stress imposed by chronic hyperglycemia [30,31].”
The role of gut–islet axis in pancreatic islet function and glucose homeostasis
Chen, Q., Gao, Y., Li, F., & Li, Y. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16225 · Cited by 20
“45 48 Apart from its multifaceted glucose-lowering effects, GLP-1 also regulates energy balance and obesity through its effects on satiety and appetite.”
Foley, J. E., & Åhrén, B. (2017) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2017.13.02.56 · Cited by 16
Simonds, S. E., Pryor, J. T., Koegler, F. H., Buch-Rasmussen, A. S., Kelly, L. E., Grove, K. L., & Cowley, M. A. (2019) · Diabetes · doi:10.2337/db18-1149 · Cited by 13
Class B1 GPCRs: insights into multireceptor pharmacology for the treatment of metabolic disease
Sangwung, P., Ho, J. D., Siddall, T., Lin, J., Tomás, A., Jones, B. J., & Sloop, K. W. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00371.2023 · Cited by 15
Evidence for Glucagon Secretion and Function Within the Human Gut
Sun, E. W. L., Martin, A. M., de Fontgalland, D., Sposato, L., Rabbitt, P., Hollington, P., Wattchow, D. A., Colella, A. D., Chataway, T., Albrechtsen, N. J. W., et al. (2021) · Endocrinology · doi:10.1210/endocr/bqab022 · Cited by 13
Vickers, S. P., Cheetham, S. C., Birmingham, G. D., Rowley, H. L., Headland, K. R., Dickinson, K., Grempler, R., Hocher, B., Mark, M., & Klein, T. (2012) · Clinical Laboratory · doi:10.7754/clin.lab.2011.110919 · Cited by 15
“Incretins are secreted from the gut in response to a meal [6] and, in the case of GLP-1, the dual effects of the stimulation of insulin secretion from β cells of the pancreas and the suppression of glucagon secretion from α cells [7-9], contribute equally to its glucose-lowering action [9].”
BackgroundAcute administration of interleukin-6 does not increase secretion of glucagon-like peptide-1 in mice
Christiansen, C. B., Jepsen, S. L., Svendsen, B., Balk-Møller, E., Dahlby, T., Kuhre, R. E., Hartmann, B., Mandrup-Poulsen, T. R., Deacon, C. F., Albrechtsen, N. J. W., et al. (2018) · Physiological Reports · doi:10.14814/phy2.13788 · Cited by 13
“leading to potentiation of glucose-induced insulin secretion (insulinotropic effects); it also inhibits the secretion of glucagon (glucagonostatic effects) (Hare et al. 2010) and through this combined action, may lower hepatic glucose production and decrease plasma glucose concentrations (Hvidberg et al.”
BackgroundSelf-citationThe Enteroendocrine System in Obesity
Miedzybrodzka, E. L., Reimann, F., & Gribble, F. M. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2022_582 · Cited by 12
Ogawa, S., Nako, K., Okamura, M., Sakamoto, T., & Ito, S. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12314 · Cited by 12
Fukumori, R., Sugino, T., Shingu, H., Moriya, N., Hasegawa, Y., Kojima, M., Kangawa, K., Obitsu, T., Kushibiki, S., & Taniguchi, K. (2011) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2011.09.005 · Cited by 12
“Additionally, these gut hormones were reported to influence insulin and glucagon secretion [11, 12].”
BackgroundIncretin-based therapy: a new horizon in diabetes management
Zarei, M., Vaighan, N. S., Farjoo, M. H., Talebi, S., & Zarei, M. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01479-3 · Cited by 13
“Nonetheless, the insuli - notropic and glucagonostatic effects of GLP-1 have been well documented [31 , 43–45 ].”
A Mechanistic Rationale for Incretin-Based Therapeutics in the Management of Obesity
Samms, R. J., & Kusminski, C. M. (2024) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022724-105443 · Cited by 12
Regulation of LEAP2 by insulin and glucagon in mice and humans
Johansen, V. B. I., Gradel, A. K. J., Holm, S. K., Cuenco, J., Merrild, C., Petersen, N., Demozay, D., Mani, B. K., Suppli, M. P., Grøndahl, M. F. G., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.101996 · Cited by 16
Self-citationZhao, X., Liu, Y., Wang, D., Li, T., Xu, Z., Li, Z., Bai, X., & Wang, Y.-C. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5515 · Cited by 12
“GLP‑1 reduces blood glucose by inhibiting glucagon secretion, an effect that is as significant as its insulinotropic action in lowering blood glucose levels, as demonstrated in a study on patients with T2DM (44).”
InfluentialViloria, K., Hewison, M., & Hodson, D. J. (2021) · The Journal of Physiology · doi:10.1113/jp280890 · Cited by 15
Per-arnt-sim (PAS) domain kinase (PASK) as a regulator of glucagon secretion
MacDonald, P. E., & Rorsman, P. (2011) · Diabetologia · doi:10.1007/s00125-011-2072-1 · Cited by 13
“The importance of glucagon has recently been underscored by the potential therapeutic value of antiglucagon approaches [4] and new insights demonstrating the importance of glucagon suppression in the glucose-lowering effects of glucagon-like peptide-1 [5].”
BackgroundOda, H., Mori, A., Lee, P., Saeki, K., Ishioka, K., Arai, T., & Sako, T. (2013) · Research in Veterinary Science · doi:10.1016/j.rvsc.2013.04.003 · Cited by 12
Wan, H., Zhao, D., Shen, J., Lu, L., Zhang, T., & Chen, Z. (2015) · Journal of Diabetes Research · doi:10.1155/2016/9849328 · Cited by 12
“and gastric inhibitory polypeptide, which in turn glucosedependently promote insulin secretion and inhibit glucagon secretion, thus helping to correct hyperglycemic states [24].”
Rieger, T. R., & Musante, C. J. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.05.006 · Cited by 10
Fujitani, Y., Fujimoto, S., TAKAHASHI, K., Satoh, H., Hirose, T., Hiyoshi, T., Ai, M., Okada, Y., Gosho, M., Mita, T., et al. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.09.014 · Cited by 10
Protein kinase C-δ signaling regulates glucagon secretion from pancreatic islets
Yamamoto, K., Mizuguchi, H., Tokashiki, N., Kobayashi, M., Tamaki, M., Sato, Y., Fukui, H., & Yamauchi, A. (2017) · The Journal of Medical Investigation · doi:10.2152/jmi.64.122 · Cited by 10
Guida, C., MIRANDA, C. A., Asterholm, I. W., Basco, D., Benrick, A., Chanclón, B., Chibalina, M. V., Harris, M., Kellard, J. A., McCulloch, L. J., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/785667 · Cited by 13
“Although this effect is thought to account for ~50% of the peptide’s hypoglycemic action (Hare et al., 2010), the cellular mechanisms underlying the glucagonostatic effect are poorly understood compared to the insulinotropic effects, which are fairly well characterized (Gromada et al., 1998).”
BackgroundTanimoto, M., Kanazawa, A., Hirose, T., Yoshihara, T., Kobayashi‐Kimura, S., Nakanishi, R., Tosaka, Y., Sasaki‐Omote, R., Kudo‐Fujimaki, K., Komiya, K., et al. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12338 · Cited by 9
Rizos, C. V., Filippatos, T. D., & Elisaf, M. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1418325 · Cited by 10
Lyu, F., Huang, B., Su, W., Yan, F., Zeng, J., Chen, Z., Zhang, Y., Wang, S.-H., Huang, Y., Zhang, M., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00758-5 · Cited by 11
“It is known that DDP-4 inhibitors can inhibit the degradation of the endogenous incretin hormones GLP-1 and gastric inhibitory polypeptide (GIP), which in turn promotes insulin secretion and inhibits glucagon secretion in a glucose-dependent manner, thus helping to correct hyperglycemic states [18].”
BackgroundTaking Aim at Islet Hormones With GLP-1: Is Insulin or Glucagon the Better Target?
D’Alessio, D. A. (2010) · Diabetes · doi:10.2337/db10-0299 · Cited by 10
“(12) revisit the glucagonostatic effects of GLP-1 in the context of fasting hyperglycemia.”
BackgroundGut Peptide Agonism in the Treatment of Obesity and Diabetes
Grandl, G., Novikoff, A., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180044 · Cited by 11
Metadata
- Authors
- Hare, K. J., Vilsbøll, T., Asmar, M., Deacon, C. F., Knop, F. K., & Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Holst, Jens J.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-07-01
- Volume
- 59
- Issue
- 7
- Pages
- 1765-1770
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2889777
- OpenAlex
- W2117402345
- Cited by
- 276
- References
- 34
- Citations by year
- 2026: 6 · 2025: 13 · 2024: 17 · 2023: 19 · 2022: 13 · 2021: 18 · 2020: 20 · 2019: 24 · 2018: 13 · 2017: 15 · 2016: 19 · 2015: 20 · 2014: 20 · 2013: 19 · 2012: 16
- FWCI
- 14.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- American Diabetes Association
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon-like peptide-1, type 2 diabetes, glucagon inhibition, insulin secretion, glucose-lowering effect, alpha cells, pancreatic beta cells, somatostatin, glucose turnover, insulin replacement therapy
- MeSH terms
- Insulin Secretion, Adult, Analysis of Variance, Blood Glucose, Diabetes Mellitus, Type 2, Glucagon, Humans, Insulin, Male, Middle Aged, Time Factors, Glucose Clamp Technique, Treatment Outcome, Area Under Curve, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.